Histone acetylation in gene regulation.

Genetic information is packaged in the highly dynamic nucleoprotein structure called chromatin. Many biological processes are regulated via post-translational modifications of key proteins. Acetylation of lysine residues at the N-terminal histone tails is one of the most studied covalent modifications influencing gene regulation in eukaryotic cells. This review focuses on the role of enzymes involved in controlling both histone and non-histone proteins acetylation levels in the cell, with particular emphasis on their effects on cancer.

[1]  Saeed Tavazoie,et al.  Mapping Global Histone Acetylation Patterns to Gene Expression , 2004, Cell.

[2]  C. Allis,et al.  Histone and chromatin cross-talk. , 2003, Current opinion in cell biology.

[3]  D. Soldati,et al.  Cloning and analysis of a Toxoplasma gondii histone acetyltransferase: a novel chromatin remodelling factor in Apicomplexan parasites. , 1999, Nucleic acids research.

[4]  O. Aparicio,et al.  H2A.Z Functions To Regulate Progression through the Cell Cycle , 2006, Molecular and Cellular Biology.

[5]  S. Henikoff,et al.  Heterochromatic deposition of centromeric histone H3-like proteins. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[6]  R Ohba,et al.  A novel histone acetyltransferase is an integral subunit of elongating RNA polymerase II holoenzyme. , 1999, Molecular cell.

[7]  C. Glass,et al.  The coregulator exchange in transcriptional functions of nuclear receptors. , 2000, Genes & development.

[8]  Roberto Sanchez,et al.  Structural mechanism of the bromodomain of the coactivator CBP in p53 transcriptional activation. , 2004, Molecular cell.

[9]  Q. Zhang,et al.  Acetylation of adenovirus E1A regulates binding of the transcriptional corepressor CtBP. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[10]  B. Aggarwal,et al.  Curcumin (Diferuloylmethane) Down-Regulates Expression of Cell Proliferation and Antiapoptotic and Metastatic Gene Products through Suppression of IκBα Kinase and Akt Activation , 2006, Molecular Pharmacology.

[11]  A. Mirsky,et al.  ACETYLATION AND METHYLATION OF HISTONES AND THEIR POSSIBLE ROLE IN THE REGULATION OF RNA SYNTHESIS. , 1964, Proceedings of the National Academy of Sciences of the United States of America.

[12]  Megan F. Cole,et al.  Genome-wide Map of Nucleosome Acetylation and Methylation in Yeast , 2005, Cell.

[13]  C. Allis,et al.  Tetrahymena Histone Acetyltransferase A: A Homolog to Yeast Gcn5p Linking Histone Acetylation to Gene Activation , 1996, Cell.

[14]  P. Pandolfi,et al.  Targeting aberrant transcriptional repression in acute myeloid leukemia. , 2003, Reviews in clinical and experimental hematology.

[15]  John R. Yates,et al.  The ADA Complex Is a Distinct Histone Acetyltransferase Complex in Saccharomyces cerevisiae , 1999, Molecular and Cellular Biology.

[16]  D. Vigushin,et al.  Histone deacetylase inhibitors in cancer treatment. , 2002, Anti-cancer drugs.

[17]  Steven J Altschuler,et al.  Genomic characterization reveals a simple histone H4 acetylation code. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[18]  L. Verdone,et al.  Common chromatin architecture, common chromatin remodeling, and common transcription kinetics of Adr1-dependent genes in Saccharomyces cerevisiae. , 2004, Biochemistry.

[19]  Xiang-Jiao Yang.  The diverse superfamily of lysine acetyltransferases and their roles in leukemia and other diseases. , 2004, Nucleic acids research.

[20]  Carlos Caldas,et al.  Mutations truncating the EP300 acetylase in human cancers , 2000, Nature Genetics.

[21]  S. Minucci,et al.  Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer , 2006, Nature Reviews Cancer.

[22]  R. Aguiar,et al.  A novel fusion between MOZ and the nuclear receptor coactivator TIF2 in acute myeloid leukemia. , 1998, Blood.

[23]  P. Grant,et al.  Transcription: A lesson in sharing? , 1998, Nature.

[24]  S. Berger,et al.  Identification of human proteins functionally conserved with the yeast putative adaptors ADA2 and GCN5 , 1996, Molecular and cellular biology.

[25]  Andrew J. Bannister,et al.  The TAFII250 Subunit of TFIID Has Histone Acetyltransferase Activity , 1996, Cell.

[26]  C. Caldas,et al.  p300/CBP and cancer , 2004, Oncogene.

[27]  P. Marks,et al.  Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells. , 2000, Journal of the National Cancer Institute.

[28]  B. Stillman,et al.  Histone Acetyltransferase HBO1 Interacts with the ORC1 Subunit of the Human Initiator Protein* , 1999, The Journal of Biological Chemistry.

[29]  B. Turner,et al.  Cellular Memory and the Histone Code , 2002, Cell.

[30]  A. Feinberg,et al.  The history of cancer epigenetics , 2004, Nature Reviews Cancer.

[31]  D. Birnbaum,et al.  A further case of acute myelomonocytic leukemia with inv(8) chromosomal rearrangement and MOZ-NCOA2 gene fusion. , 2003, International journal of molecular medicine.

[32]  司履生.  Cancer epigenetics , 2006 .

[33]  V. Saha,et al.  Chromatin Modification, Leukaemia and Implications for Therapy , 2002, British journal of haematology.

[34]  Rachel Maria Imoberdorf,et al.  A Role for Gcn5-Mediated Global Histone Acetylation in Transcriptional Regulation , 2006, Molecular and Cellular Biology.

[35]  A. Wolffe,et al.  Targeting of N‐CoR and histone deacetylase 3 by the oncoprotein v‐ErbA yields a chromatin infrastructure‐dependent transcriptional repression pathway , 2000, The EMBO journal.

[36]  J. Workman,et al.  The many HATs of transcription coactivators. , 2000, Trends in biochemical sciences.

[37]  K. Blanchard,et al.  Acute mixed lineage leukemia with an inv(8)(p11q13) resulting in fusion of the genes for MOZ and TIF2. , 1998, Blood.

[38]  J. Workman,et al.  Function and Selectivity of Bromodomains in Anchoring Chromatin-Modifying Complexes to Promoter Nucleosomes , 2002, Cell.

[39]  L. Guarente,et al.  Negative control of p53 by Sir2alpha promotes cell survival under stress. , 2001, Cell.

[40]  P. Laird.  Cancer epigenetics. , 2005, Human molecular genetics.

[41]  D. Tremethick,et al.  Regions of variant histone His2AvD required for Drosophila development , 1999, Nature.

[42]  Peter A. Jones,et al.  The fundamental role of epigenetic events in cancer , 2002, Nature Reviews Genetics.

[43]  R Ohba,et al.  Yeast Gcn5 functions in two multisubunit complexes to acetylate nucleosomal histones: characterization of an Ada complex and the SAGA (Spt/Ada) complex. , 1997, Genes & development.

[44]  Naoyuki Fujita,et al.  Mi-2/NuRD: multiple complexes for many purposes. , 2004, Biochimica et biophysica acta.

[45]  R. Glaser,et al.  Histone H2A.Z Is Widely but Nonrandomly Distributed in Chromosomes of Drosophila melanogaster * , 2000, The Journal of Biological Chemistry.

[46]  Ping Zhu,et al.  Induction of HDAC2 expression upon loss of APC in colorectal tumorigenesis. , 2004, Cancer cell.

[47]  M. Esteller.  Epigenetics provides a new generation of oncogenes and tumour-suppressor genes. , 2007, British journal of cancer.

[48]  Wolfgang Fischle,et al.  Binary switches and modification cassettes in histone biology and beyond , 2003, Nature.

[49]  R. Evans,et al.  Acquisition of oncogenic potential by RAR chimeras in acute promyelocytic leukemia through formation of homodimers. , 2000, Molecular cell.

[50]  G. Nicolson,et al.  Expression of the metastasis‐associated MTA1 protein and its relationship to deacetylation of the histone H4 in esophageal squamous cell carcinomas , 2004, International journal of cancer.

[51]  Lei Zeng,et al.  Structure and ligand of a histone acetyltransferase bromodomain , 1999, Nature.

[52]  C. Glass,et al.  Signal-specific co-activator domain requirements for Pit-1 activation , 1998, Nature.

[53]  M. Dokmanovic,et al.  Prospects: Histone deacetylase inhibitors , 2005, Journal of cellular biochemistry.

[54]  E. Appella,et al.  Impairment of p53 acetylation, stability and function by an oncogenic transcription factor , 2004, The EMBO journal.

[55]  David Newsome,et al.  Gene Dosage–Dependent Embryonic Development and Proliferation Defects in Mice Lacking the Transcriptional Integrator p300 , 1998, Cell.

[56]  Zigang Dong,et al.  Post-translational modification of p53 in tumorigenesis , 2004, Nature Reviews Cancer.

[57]  C. Allis,et al.  Linking the epigenetic ‘language’ of covalent histone modifications to cancer , 2004, British Journal of Cancer.

[58]  J. Pérez-Ortín,et al.  HAT1 and HAT2 Proteins Are Components of a Yeast Nuclear Histone Acetyltransferase Enzyme Specific for Free Histone H4* , 1998, The Journal of Biological Chemistry.

[59]  M. Mayford,et al.  CBP Histone Acetyltransferase Activity Is a Critical Component of Memory Consolidation , 2004, Neuron.

[60]  F. Robert,et al.  H2A.Z Is Required for Global Chromatin Integrity and for Recruitment of RNA Polymerase II under Specific Conditions , 2001, Molecular and Cellular Biology.

[61]  S. Schreiber,et al.  Histone Variant H2A.Z Marks the 5′ Ends of Both Active and Inactive Genes in Euchromatin , 2006, Cell.

[62]  M. Fraga,et al.  Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer , 2005, Nature Genetics.

[63]  G. Felsenfeld,et al.  Silencing of transgene transcription precedes methylation of promoter DNA and histone H3 lysine 9 , 2004, The EMBO journal.

[64]  R. Evans,et al.  Molecular genetics of acute promyelocytic leukemia. , 1999, Trends in genetics : TIG.

[65]  R. Marmorstein.  Protein modules that manipulate histone tails for chromatin regulation , 2001, Nature Reviews Molecular Cell Biology.

[66]  G. Kong,et al.  Metastasis‐associated protein 1 enhances stability of hypoxia‐inducible factor‐1α protein by recruiting histone deacetylase 1 , 2006, The EMBO journal.

[67]  P. Grant,et al.  NuA4, an essential transcription adaptor/histone H4 acetyltransferase complex containing Esa1p and the ATM‐related cofactor Tra1p , 1999, The EMBO journal.

[68]  K. Struhl,et al.  Histone Acetylation at Promoters Is Differentially Affected by Specific Activators and Repressors , 2001, Molecular and Cellular Biology.

[69]  E. Wang,et al.  TAF1 Histone Acetyltransferase Activity in Sp1 Activation of the Cyclin D1 Promoter , 2005, Molecular and Cellular Biology.

[70]  J. Esteve,et al.  Type I MOZ/CBP (MYST3/CREBBP) is the most common chimeric transcript in acute myeloid leukemia with t(8;16)(p11;p13) translocation , 2004, Genes, chromosomes & cancer.

[71]  J. Herman,et al.  Gene silencing in cancer in association with promoter hypermethylation. , 2003, The New England journal of medicine.

[72]  P. Pelicci,et al.  Effects of the acute myeloid leukemia--associated fusion proteins on nuclear architecture. , 2001, Seminars in hematology.

[73]  Jiuhong Kang,et al.  Nickel-induced histone hypoacetylation: the role of reactive oxygen species. , 2003, Toxicological sciences : an official journal of the Society of Toxicology.

[74]  William Arbuthnot Sir Lane,et al.  The c-MYC Oncoprotein Is a Substrate of the Acetyltransferases hGCN5/PCAF and TIP60 , 2004, Molecular and Cellular Biology.

[75]  A. Feinberg,et al.  Hypomethylation distinguishes genes of some human cancers from their normal counterparts , 1983, Nature.

[76]  L. Ngo,et al.  Histone deacetylase (HDAC) inhibitor activation of p21WAF1 involves changes in promoter-associated proteins, including HDAC1. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[77]  L. Verdone,et al.  Chromatin remodeling during Saccharomyces cerevisiae ADH2 gene activation , 1996, Molecular and cellular biology.

[78]  C. Allis,et al.  Histone acetyltransferases. , 2001, Annual review of biochemistry.

[79]  C. Peterson,et al.  Histones and histone modifications , 2004, Current Biology.

[80]  G. Perez,et al.  Role of thioredoxin in the response of normal and transformed cells to histone deacetylase inhibitors. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[81]  Carlos Caldas,et al.  Chromatin modifier enzymes, the histone code and cancer. , 2005, European journal of cancer.

[82]  B. Turner,et al.  Essential and redundant functions of histone acetylation revealed by mutation of target lysines and loss of the Gcn5p acetyltransferase , 1998, The EMBO journal.

[83]  B. Franklin Pugh,et al.  Genome-Wide Relationships between TAF1 and Histone Acetyltransferases in Saccharomyces cerevisiae , 2006, Molecular and Cellular Biology.

[84]  M. Grunstein,et al.  Hyperacetylation of chromatin at the ADH2 promoter allows Adr1 to bind in repressed conditions , 2002, The EMBO journal.

[85]  Ioannis Xenarios,et al.  Microarray Deacetylation Maps Determine Genome-Wide Functions for Yeast Histone Deacetylases , 2002, Cell.

[86]  Mathieu Blanchette,et al.  Variant Histone H2A.Z Is Globally Localized to the Promoters of Inactive Yeast Genes and Regulates Nucleosome Positioning , 2005, PLoS biology.

[87]  D. Edmondson,et al.  Mammalian GCN5 and P/CAF Acetyltransferases Have Homologous Amino-Terminal Domains Important for Recognition of Nucleosomal Substrates , 1998, Molecular and Cellular Biology.

[88]  S. Berger,et al.  Histone modifications in transcriptional regulation. , 2002, Current opinion in genetics & development.

[89]  MOZ-TIF2, but Not BCR-ABL, Confers Properties of Leukemic Stem Cells to Committed Murine Hematopoietic Progenitors. , 2004 .

[90]  R. Weinberg,et al.  hSIR2SIRT1 Functions as an NAD-Dependent p53 Deacetylase , 2001, Cell.

[91]  J. Workman,et al.  Preferential occupancy of histone variant H2AZ at inactive promoters influences local histone modifications and chromatin remodeling. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[92]  J H Waterborg,et al.  Dynamics of histone acetylation in Saccharomyces cerevisiae. , 2001, Biochemistry.

[93]  N. Dhillon,et al.  Breaking through to the other side: silencers and barriers. , 2002, Current opinion in genetics & development.

[94]  D. Koshland,et al.  Cse4p Is a Component of the Core Centromere of Saccharomyces cerevisiae , 1998, Cell.

[95]  R. Kornberg,et al.  Twenty-Five Years of the Nucleosome, Fundamental Particle of the Eukaryote Chromosome , 1999, Cell.

[96]  M. Esteller.  Aberrant DNA methylation as a cancer-inducing mechanism. , 2005, Annual review of pharmacology and toxicology.

[97]  S. Minucci,et al.  Oligomerization of RAR and AML1 transcription factors as a novel mechanism of oncogenic activation. , 2000, Molecular cell.

[98]  J. Nevins,et al.  Replication Factors MCM2 and ORC1 Interact with the Histone Acetyltransferase HBO1* , 2001, The Journal of Biological Chemistry.

[99]  R. Tjian,et al.  Structure and function of a human TAFII250 double bromodomain module. , 2000, Science.

[100]  Michael Grunstein,et al.  Histone acetylation and deacetylation in yeast , 2003, Nature Reviews Molecular Cell Biology.

[101]  C. Glass,et al.  Transcription factor-specific requirements for coactivators and their acetyltransferase functions. , 1998, Science.

[102]  H. Erdjument-Bromage,et al.  Elongator, a multisubunit component of a novel RNA polymerase II holoenzyme for transcriptional elongation. , 1999, Molecular cell.

[103]  S. Minucci,et al.  The histone acetylase PCAF is a nuclear receptor coactivator. , 1998, Genes & development.

[104]  Esteban Ballestar,et al.  Methyl‐CpG binding proteins identify novel sites of epigenetic inactivation in human cancer , 2003, The EMBO journal.

[105]  B. Cairns,et al.  Transcriptional inhibition of genes with severe histone h3 hypoacetylation in the coding region. , 2002, Molecular cell.

[106]  Udaykumar Ranga,et al.  Curcumin, a Novel p300/CREB-binding Protein-specific Inhibitor of Acetyltransferase, Represses the Acetylation of Histone/Nonhistone Proteins and Histone Acetyltransferase-dependent Chromatin Transcription* , 2004, Journal of Biological Chemistry.

[107]  N. Bertos,et al.  Identification of a Human Histone Acetyltransferase Related to Monocytic Leukemia Zinc Finger Protein* , 1999, The Journal of Biological Chemistry.

[108]  S. Horvath,et al.  Global histone modification patterns predict risk of prostate cancer recurrence , 2005, Nature.

[109]  J Wu,et al.  Highly specific antibodies determine histone acetylation site usage in yeast heterochromatin and euchromatin. , 2001, Molecular cell.

[110]  Silvio Massa,et al.  Histone deacetylation in epigenetics: An attractive target for anticancer therapy , 2005, Medicinal research reviews.

[111]  Delin Chen,et al.  Negative Control of p53 by Sir2α Promotes Cell Survival under Stress , 2001, Cell.

[112]  J. Herman,et al.  Dependence of histone modifications and gene expression on DNA hypermethylation in cancer. , 2002, Cancer research.

[113]  David M. Livingston,et al.  E2F-Dependent Histone Acetylation and Recruitment of the Tip60 Acetyltransferase Complex to Chromatin in Late G1 , 2004, Molecular and Cellular Biology.

[114]  Andrew J. Bannister,et al.  The CBP co-activator is a histone acetyltransferase , 1996, Nature.

[115]  Michael Grunstein,et al.  Global histone acetylation and deacetylation in yeast , 2000, Nature.

[116]  K. Struhl,et al.  Dynamics of global histone acetylation and deacetylation in vivo: rapid restoration of normal histone acetylation status upon removal of activators and repressors. , 2002, Genes & development.

[117]  S. Minucci,et al.  Retinoid receptors in health and disease: co-regulators and the chromatin connection. , 1999, Seminars in cell & developmental biology.

[118]  R. Goodman,et al.  CBP/p300 in cell growth, transformation, and development. , 2000, Genes & development.

[119]  James Bradner,et al.  Inhibition of Histone Deacetylase 6 Acetylates and Disrupts the Chaperone Function of Heat Shock Protein 90 , 2005, Journal of Biological Chemistry.

[120]  S. Berger,et al.  Genetic isolation of ADA2: A potential transcriptional adaptor required for function of certain acidic activation domains , 1992, Cell.

[121]  Delin Chen,et al.  Deacetylation of p53 modulates its effect on cell growth and apoptosis , 2000, Nature.

[122]  G. Thireos,et al.  Two distinct yeast transcriptional activators require the function of the GCN5 protein to promote normal levels of transcription. , 1992, The EMBO journal.

[123]  Michael R. Green,et al.  Redundant roles for the TFIID and SAGA complexes in global transcription , 2000, Nature.

[124]  C. Bradbury,et al.  Histone deacetylases in acute myeloid leukaemia show a distinctive pattern of expression that changes selectively in response to deacetylase inhibitors , 2005, Leukemia.

[125]  L. Pan,et al.  Disease-related potential of mutations in transcriptional cofactors CREB-binding protein and p300 in leukemias. , 2004, Cancer letters.

[126]  L. Verdone,et al.  Role of histone acetylation in the control of gene expression. , 2005, Biochemistry and cell biology = Biochimie et biologie cellulaire.

[127]  N. Shiama.  The p300/CBP family: integrating signals with transcription factors and chromatin. , 1997, Trends in cell biology.

[128]  Xiang-Jiao Yang,et al.  Lysine acetylation and the bromodomain: a new partnership for signaling , 2004, BioEssays : news and reviews in molecular, cellular and developmental biology.

[129]  M. Parthun,et al.  Recruitment of the Type B Histone Acetyltransferase Hat1p to Chromatin Is Linked to DNA Double-Strand Breaks , 2006, Molecular and Cellular Biology.

[130]  Vigushin Dm,et al.  Histone deacetylase inhibitors in cancer treatment. , 2002 .

[131]  C. Disteche,et al.  The translocation t(8;16)(p11;p13) of acute myeloid leukaemia fuses a putative acetyltransferase to the CREB–binding protein , 1996, Nature Genetics.

[132]  D. Livingston,et al.  Gene dose-dependent control of hematopoiesis and hematologic tumor suppression by CBP. , 2000, Genes & development.

[133]  J. H. Waterborg,et al.  Steady-state Levels of Histone Acetylation in Saccharomyces cerevisiae * , 2000, The Journal of Biological Chemistry.

[134]  D. Schübeler,et al.  A New Map for Navigating the Yeast Epigenome , 2005, Cell.

[135]  L. Kedes,et al.  Differential roles of p300 and PCAF acetyltransferases in muscle differentiation. , 1997, Molecular cell.

[136]  R. Sternglanz,et al.  Identification of a Gene Encoding a Yeast Histone H4 Acetyltransferase (*) , 1995, The Journal of Biological Chemistry.

[137]  T. Heinzel,et al.  Histone deacetylase as a therapeutic target , 2001, Trends in Endocrinology & Metabolism.

[138]  T. Richmond,et al.  Crystal structure of the nucleosome core particle at 2.8 Å resolution , 1997, Nature.

[139]  M. Toyota,et al.  Epigenetic changes in solid and hematopoietic tumors. , 2005, Seminars in oncology.

[140]  P. Brown,et al.  Coordinate regulation of yeast ribosomal protein genes is associated with targeted recruitment of Esa1 histone acetylase. , 2000, Molecular cell.

[141]  Min-Su Kim,et al.  Co-activation of Atrial Natriuretic Factor Promoter by Tip60 and Serum Response Factor* , 2006, Journal of Biological Chemistry.

[142]  S. Berger,et al.  Cloning of Drosophila GCN5: conserved features among metazoan GCN5 family members. , 1998, Nucleic acids research.

[143]  F. Dequiedt,et al.  Class II histone deacetylases: versatile regulators. , 2003, Trends in genetics : TIG.

[144]  Stuart L Schreiber,et al.  Deacetylase enzymes: biological functions and the use of small-molecule inhibitors. , 2002, Chemistry & biology.

[145]  E. Kandel,et al.  Chromatin Acetylation, Memory, and LTP Are Impaired in CBP+/− Mice A Model for the Cognitive Deficit in Rubinstein-Taybi Syndrome and Its Amelioration , 2004, Neuron.

[146]  V. Richon,et al.  Histone deacetylase inhibitors as new cancer drugs , 2001, Current opinion in oncology.

[147]  Yufeng Shi,et al.  Curcumin-induced histone hypoacetylation: the role of reactive oxygen species. , 2005, Biochemical pharmacology.

[148]  Michael R. Green,et al.  Dissecting the Regulatory Circuitry of a Eukaryotic Genome , 1998, Cell.

[149]  C. Allis,et al.  The language of covalent histone modifications , 2000, Nature.

[150]  B. Hamkalo,et al.  The distribution of somatic H1 subtypes is non-random on active vs. inactive chromatin: Distribution in human fetal fibroblasts , 2004, Chromosome Research.

[151]  W. D. Cress,et al.  Histone deacetylases, transcriptional control, and cancer , 2000, Journal of cellular physiology.

[152]  L. Stephens,et al.  Metastasis Tumor Antigen Family Proteins during Breast Cancer Progression and Metastasis in a Reliable Mouse Model for Human Breast Cancer , 2006, Clinical Cancer Research.

[153]  S. Buratowski,et al.  Bromodomain factor 1 corresponds to a missing piece of yeast TFIID. , 2000, Genes & development.

[154]  Xin Bian,et al.  Ku70 acetylation mediates neuroblastoma cell death induced by histone deacetylase inhibitors. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[155]  C. Glass,et al.  Defect of histone acetyltransferase activity of the nuclear transcriptional coactivator CBP in Rubinstein-Taybi syndrome. , 2001, Human molecular genetics.

[156]  B. Cairns,et al.  Genome-Wide Dynamics of Htz1, a Histone H2A Variant that Poises Repressed/Basal Promoters for Activation through Histone Loss , 2005, Cell.

[157]  B. Johansson,et al.  Acute Myeloid Leukemia with inv(8)(p11q13) , 2000, Leukemia & lymphoma.

[158]  K. Packman,et al.  Histone deacetylase inhibitors differentially stabilize acetylated p53 and induce cell cycle arrest or apoptosis in prostate cancer cells , 2005, Cell Death and Differentiation.

[159]  J. Herman,et al.  Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer , 1999, Nature Genetics.

[160]  Jonathan Widom,et al.  The Major Cytoplasmic Histone Acetyltransferase in Yeast: Links to Chromatin Replication and Histone Metabolism , 1996, Cell.

[161]  John R Yates,et al.  Acetylation by Tip60 Is Required for Selective Histone Variant Exchange at DNA Lesions , 2004, Science.

[162]  D. Sterner,et al.  Acetylation of Histones and Transcription-Related Factors , 2000, Microbiology and Molecular Biology Reviews.

[163]  Peter A. Jones,et al.  A blueprint for a Human Epigenome Project: the AACR Human Epigenome Workshop. , 2005, Cancer research.